Website
News25/Ratings10
News · 26 weeks34-87%
2025-10-262026-04-19
Mix2490d
- Other11(46%)
- SEC Filings7(29%)
- Insider4(17%)
- Earnings2(8%)
Latest news
25 items- PRHarrow Announces the Issuance of J-Code for IOPIDINE® 1%NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent J-Code (J2374) by the Centers for Medicare & Medicaid Services (CMS). Effective July 1, 2026, IOPIDINE 1% will be reimbursed when administered in the in-office setting. J-Codes are CMS billing designations that allow physicians to be reimbursed directly for drugs administered in their offices. The assignment of a permanent J-Code removes a longstanding practical barrier to routine use of IOPIDINE 1% for office-based procedur
- PRLogiCare3PL Selected as Distribution Partner by HarrowOLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026, LogiCare3PL is providing both non-title and 3PL title distribution services, supporting distribution of Harrow's products across the U.S. market. LogiCare3PL was selected for its high-touch service model, proven ability to execute quickly and efficiently, and commitment to building a long-term partnership. These capabilities were e
- SECHarrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Harrow Inc.SCHEDULE 13G/A - HARROW, INC. (0001360214) (Subject)
- SECHarrow Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the "Offering") of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is
- SECHarrow Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support GrowthNASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subjec
- PRHarrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual MeetingNASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE® (cyclosporine ophthalmic solution) 0.1% and ILEVRO® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C. The accepted research underscores Harrow's continued commitment to advancing evidence-based treatment options for ophthalmic diseases, including
- SECHarrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- INSIDERLarge owner Opaleye Management Inc. sold $7,846,426 worth of shares (198,572 units at $39.51) (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- PRHarrow to Present at Leerink Partner's 2026 Global Healthcare ConferenceNASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner's 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida. The presentation will be webcast live and can be found on the Company's website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, Inc. (NASDAQ:HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front a
- INSIDERLarge owner Opaleye Management Inc. sold $270,900 worth of shares (5,000 units at $54.18) (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- PRHarrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery IndicationNASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial evaluating TRIESENCE (preservative-free triamcinolone acetonide injectable suspension) 40 mg/mL for the treatment of ocular inflammation and pain following cataract surgery. The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical trial designed to evaluate the safety and efficacy of TRIESENCE in patients undergoing cataract surger
- SECSEC Form 10-K filed by Harrow Inc.10-K - HARROW, INC. (0001360214) (Filer)
- SECHarrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial GuidanceFourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of
- PRHarrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on
- PRHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ KitsNASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company's commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaPack kits expand access to FDA-approved ophthalmic products for the millions of Americans each year who require infection control and treatment of pain and inflammation associated with cataract surgery. PharmaPack kits also remove insurance-related administrative complexity and reduce regul
- PROSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in CaliforniaThe Montana-based compounder commits to supporting prescribers and patients in wake of competitor's abrupt exit of California market OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor. According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement rea
- INSIDERSEC Form 4 filed by CHIEF COMMERCIAL OFFICER Sullivan Patrick William4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sullivan Patrick William3 - HARROW, INC. (0001360214) (Issuer)
- SECHarrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong GrowthDoubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to Unify Branding under Harrow Patrick W. Sullivan Promoted to Serve as Harrow's Chief Commercial Officer MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow's ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy NASHVILLE, Tenn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today reaffirmed its
- INSIDERLarge owner Opaleye Management Inc. sold $1,066,914 worth of shares (20,000 units at $53.35) (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)